Patents Assigned to Cerebral Therapeutics, Inc.
  • Publication number: 20240139487
    Abstract: An implantable cranial medical device includes a housing configured to be positioned on a skull of a subject such that at least a portion of the housing covers a burr hole of the skull. The medical device also includes a brain catheter connector extending from the housing and configured to extend within the skull. The brain catheter connector includes a first connector and a second connector. The second connector extends farther away from the housing than the first connector. Additionally, the medical device includes a first fluid path extending through the housing and the first connector, and a second fluid path extending through the housing and the second connector. The first and second fluid paths are not in fluid communication with one another within the housing.
    Type: Application
    Filed: October 31, 2023
    Publication date: May 2, 2024
    Applicant: Cerebral Therapeutics, Inc.
    Inventors: Dwight A. Skinner, Felix E. Robles Toth
  • Publication number: 20230321413
    Abstract: An implantable cranial medical device includes a first fluid flow path, a second fluid flow path, and upper flange portion, and a lower portion. The upper flange portion is configured to rest on a skull of a subject about a burr hole. The lower portion is configured to be placed within the burr hole. The first fluid flow path may extend from a first opening in the upper flange portion to a first opening in the lower portion. The second fluid flow path may extend from a second opening in the upper flange portion to a second opening in the lower portion.
    Type: Application
    Filed: June 9, 2023
    Publication date: October 12, 2023
    Applicant: Cerebral Therapeutics, Inc.
    Inventors: Daniel J. Abrams, Lisa Lynn Shafer, Arindam Datta, Thomas R. Prentice, Paul Rumpza, Felix Ernesto Robles Toth, Jordan Jacobs, John Butziger
  • Publication number: 20230277840
    Abstract: A burr hole device is configured to receive a catheter and a cable of a sheath. The sheath is configured to receive a portion of the catheter and has an electrode. When the catheter and sheath are implanted with the burr hole device, the catheter and electrode of the sheath are implanted in a brain. Systems and apparatuses may include the burr hole device and/or a cranial port device, the catheter, and the sheath.
    Type: Application
    Filed: February 10, 2023
    Publication date: September 7, 2023
    Applicant: Cerebral Therapeutics, Inc.
    Inventors: Daniel J. Abrams, Matias Maturana, Ross Thomas, Christopher Smith
  • Publication number: 20230091409
    Abstract: In some embodiments, a device may include an intraventricular access device and an infusion device. The intraventricular access device may include more than one catheter and a container. In some embodiments, the catheter may include an aspiration lumen and an infusion lumen. A distal end of the intraventricular portion of the catheter may be positionable, during use, in a subject's brain fluid. In some embodiments, the container may be coupled to a proximal end of the aspiration lumen. The proximal end of the aspiration lumen may be in fluid communication with the container. The proximal end of the infusion lumen may be in communication with an infusion pump. In some embodiments, the device inhibits cross contamination between a first fluid in the aspiration lumen and a second fluid in the infusion lumen.
    Type: Application
    Filed: November 28, 2022
    Publication date: March 23, 2023
    Applicant: Cerebral Therapeutics, Inc.
    Inventors: Daniel J. Abrams, Michael S. Canney
  • Publication number: 20230000804
    Abstract: Highly concentrated solutions are disclosed along with methods of inhibiting and/or ameliorating functional neurological disorders of the brain. The method may include administering directly to a brain of a subject a medicament multiple times over a time period of at least two days. The medicament may include a half-life of less than 2 hour in the cerebrospinal fluid. The method may include inhibiting and/or ameliorating a functional neurological disorder of the brain using the medicant.
    Type: Application
    Filed: September 2, 2022
    Publication date: January 5, 2023
    Applicants: Cerebral Therapeutics, Inc., The Regents of the University of Colorado, a body corporate
    Inventors: Daniel J. Abrams, Thomas Joseph Anchordoquy
  • Publication number: 20220409530
    Abstract: A method of treating a subject which may be a human suffering from epilepsy which may be a form of epilepsy resistant to treatment and particular patients which are resistant to treatment with oral medication. The method involves positioning a catheter device in the subject's brain and infusing a liquid formulation of a drug into a portion of the subject's brain through an infusion lumen at a rate of 5, 4, 3, 2, or 1 ml or less per day ±50%. The infusion may be constant and corrected by aspirating fluid from the patient's brain and testing the aspirated fluid for drug concentration. The rate of infusion by the formulation and the concentration of drug may be adjusted based on patient responsiveness.
    Type: Application
    Filed: September 1, 2022
    Publication date: December 29, 2022
    Applicant: Cerebral Therapeutics, Inc.
    Inventors: Daniel J. Abrams, Michael S. Canney
  • Patent number: 11511035
    Abstract: In some embodiments, a device may include an intraventricular access device and an infusion device. The intraventricular access device may include more than one catheter and a container. In some embodiments, the catheter may include an aspiration lumen and an infusion lumen. A distal end of the intraventricular portion of the catheter may be positionable, during use, in a subject's brain fluid. In some embodiments, the container may be coupled to a proximal end of the aspiration lumen. The proximal end of the aspiration lumen may be in fluid communication with the container. In some embodiments, the container may include a barrier positioned between a proximal opening of the aspiration lumen and at least a portion of the infusion lumen adjacent to and/or associated with the container. The barrier may inhibit penetration of a surgical instrument.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: November 29, 2022
    Assignee: CEREBRAL THERAPEUTICS, INC.
    Inventors: Daniel J. Abrams, Michael S. Canney
  • Publication number: 20220331567
    Abstract: An implantable cranial medical device includes a first fluid flow path, a second fluid flow path, and upper flange portion, and a lower portion. The upper flange portion is configured to rest on a skull of a subject about a burr hole. The lower portion is configured to be placed within the burr hole. The first fluid flow path may extend from a first opening in the upper flange portion to a first opening in the lower portion. The second fluid flow path may extend from a second opening in the upper flange portion to a second opening in the lower portion.
    Type: Application
    Filed: July 1, 2022
    Publication date: October 20, 2022
    Applicant: Cerebral Therapeutics, Inc.
    Inventor: Daniel J. Abrams
  • Patent number: 11433038
    Abstract: Highly concentrated solutions are disclosed along with methods of inhibiting and/or ameliorating functional neurological disorders of the brain. The method may include administering directly to a brain of a subject a medicament multiple times over a time period of at least two days. The medicament may include a half-life of less than 2 hour in the cerebrospinal fluid. The method may include inhibiting and/or ameliorating a functional neurological disorder of the brain using the medicant.
    Type: Grant
    Filed: April 16, 2020
    Date of Patent: September 6, 2022
    Assignees: Cerebral Therapeutics, Inc., The Regents of the University of Colorado
    Inventors: Daniel J. Abrams, Thomas Joseph Anchordoquy
  • Patent number: 10772857
    Abstract: Highly concentrated solutions are disclosed along with methods of inhibiting and/or ameliorating functional neurological disorders of the brain. The method may include administering directly to a brain of a subject a medicament multiple times over a time period of at least two days. The medicament may include a half-life of less than 2 hour in the cerebrospinal fluid. The method may include inhibiting and/or ameliorating a functional neurological disorder of the brain using the medicant.
    Type: Grant
    Filed: October 23, 2018
    Date of Patent: September 15, 2020
    Assignee: Cerebral Therapeutics, Inc.
    Inventors: Daniel J. Abrams, Thomas Joseph Anchordoguy